Outcome of treatment with carfilzomib before and after treatment with daratumumab in relapsed or refractory multiple myeloma patients.
Højholt KL, Gregersen H, Szabo AG, Klausen TW, Levring MB, Preiss B, Helleberg C, Breinholt MF, Hermansen E, Rahbek Gjerdrum LM, Bønløkke ST, Nielsen K, Kjeldsen E, Iversen KF, Teodorescu EM, Kurt E, Strandholdt C, Andersen MK, Vangsted AJ.
Højholt KL, et al.
Hematol Oncol. 2021 Oct;39(4):521-528. doi: 10.1002/hon.2906. Epub 2021 Aug 2.
Hematol Oncol. 2021.
PMID: 34342035